U.S., Jan. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07313150) titled 'A Phase I Trial of Subcutaneous QLS7305 in Healthy Adults' on Nov. 14, 2025.
Brief Summary: The goal of this clinical trial is to evaluate the safety, tolerability, and preliminary characteristics of the investigational drug QLS7305 in healthy adult participants in China. The main questions it aims to answer are:
What is the safety and tolerability profile of single and multiple subcutaneous doses of QLS7305 in healthy adults? What are the pharmacokinetic (PK) characteristics of QLS7305 and its major metabolites? What are the pharmacodynamic (PD) effects of QLS7305 on the complement system (e.g., serum C3 levels and complement activ...